In the rapidly advancing realm of medical innovation, cell and gene therapies stand out as potential game-changers for treating life-threatening diseases, yet they face formidable obstacles on the path to market. The U.S. Food and Drug Administration (FDA) has increasingly postponed or denied
In a nation heavily reliant on a steady supply of life-saving medications, the stark reality that many pharmaceutical manufacturing facilities are situated in regions increasingly vulnerable to natural disasters raises profound concerns. From hurricanes tearing through coastal areas to wildfires
In a world where organ shortages and chronic diseases continue to challenge healthcare systems globally, 3D Systems, a titan in additive manufacturing, is stepping up with groundbreaking solutions in regenerative medicine. This innovative field, which focuses on creating living tissues and organs
The U.S. pharmaceutical sector finds itself at a critical juncture with the rollout of President Donald J. Trump’s SAPIR (Strategic Active Pharmaceutical Ingredients Reserve) Initiative, a groundbreaking policy introduced via an Executive Order on August 13 of this year. This ambitious plan seeks
The viral vector and plasmid DNA manufacturing market stands at the threshold of a transformative era, propelled by an escalating demand for gene therapies, vaccines, and personalized medical solutions that are reshaping the landscape of healthcare. These technologies, essential for delivering
In a significant move to strengthen the pharmaceutical landscape in the United States, AbbVie, a prominent player in the industry, has unveiled a substantial $195 million investment to enhance its active pharmaceutical ingredient (API) manufacturing capabilities at its North Chicago, Illinois
